323 related articles for article (PubMed ID: 33966491)
1. Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.
Demchuk AM; Yue P; Zotova E; Nakamya J; Xu L; Milling TJ; Ohara T; Goldstein JN; Middeldorp S; Verhamme P; Lopez-Sendon JL; Conley PB; Curnutte JT; Eikelboom JW; Crowther M; Connolly SJ;
Stroke; 2021 Jun; 52(6):2096-2105. PubMed ID: 33966491
[TBL] [Abstract][Full Text] [Related]
2. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
[TBL] [Abstract][Full Text] [Related]
3. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan.
Toyoda K; Arakawa S; Ezura M; Kobayashi R; Tanaka Y; Hasegawa S; Yamashiro S; Komatsu Y; Terasawa Y; Masuno T; Kobayashi H; Oikawa S; Yasaka M
J Atheroscler Thromb; 2024 Mar; 31(3):201-213. PubMed ID: 37635060
[TBL] [Abstract][Full Text] [Related]
4. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
[TBL] [Abstract][Full Text] [Related]
5. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Connolly SJ; Milling TJ; Eikelboom JW; Gibson CM; Curnutte JT; Gold A; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Goodman S; Leeds J; Wiens BL; Siegal DM; Zotova E; Meeks B; Nakamya J; Lim WT; Crowther M;
N Engl J Med; 2016 Sep; 375(12):1131-41. PubMed ID: 27573206
[TBL] [Abstract][Full Text] [Related]
6. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
Connolly SJ; Crowther M; Eikelboom JW; Gibson CM; Curnutte JT; Lawrence JH; Yue P; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Demchuk AM; Pallin DJ; Concha M; Goodman S; Leeds J; Souza S; Siegal DM; Zotova E; Meeks B; Ahmad S; Nakamya J; Milling TJ;
N Engl J Med; 2019 Apr; 380(14):1326-1335. PubMed ID: 30730782
[TBL] [Abstract][Full Text] [Related]
7. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
Giovino A; Shomo E; Busey KV; Case D; Brockhurst A; Concha M
Clin Neurol Neurosurg; 2020 Aug; 195():106070. PubMed ID: 32679541
[TBL] [Abstract][Full Text] [Related]
8. Andexanet Alfa (Andexxa) Formulary Review.
Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
[TBL] [Abstract][Full Text] [Related]
9. Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care.
Huttner HB; Gerner ST; Kuramatsu JB; Connolly SJ; Beyer-Westendorf J; Demchuk AM; Middeldorp S; Zotova E; Altevers J; Andersohn F; Christoph MJ; Yue P; Stross L; Schwab S
Stroke; 2022 Feb; 53(2):532-543. PubMed ID: 34645283
[TBL] [Abstract][Full Text] [Related]
10. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
[TBL] [Abstract][Full Text] [Related]
11. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
Maragkos GA; Nelton EB; Richter S; Stippler M
World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ
J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa.
Nederpelt CJ; Naar L; Sylvester KW; Barra ME; Roberts RJ; Velmahos GC; Kaafarani HMA; Rosenthal MG; King DR
J Thromb Haemost; 2020 Oct; 18(10):2532-2541. PubMed ID: 32738161
[TBL] [Abstract][Full Text] [Related]
14. [Andexanet alfa (ONDEXXYA
Yajima T; Higashimori M; Takata C; Sasabe T
Nihon Yakurigaku Zasshi; 2023; 158(1):89-100. PubMed ID: 36596498
[TBL] [Abstract][Full Text] [Related]
15. Real-world utilization of andexanet alfa.
Brown CS; Scott RA; Sridharan M; Rabinstein AA
Am J Emerg Med; 2020 Apr; 38(4):810-814. PubMed ID: 31870672
[TBL] [Abstract][Full Text] [Related]
16. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
Lipari L; Yang S; Milligan B; Blunck J
Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
[TBL] [Abstract][Full Text] [Related]
17. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
[TBL] [Abstract][Full Text] [Related]
18. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures.
Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA
Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083
[TBL] [Abstract][Full Text] [Related]
19. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
[TBL] [Abstract][Full Text] [Related]
20. The use of andexanet alpha in the Polish setting: An interdisciplinary protocol. Expert consensus statement of the Polish Cardiac Society.
Kazimierczyk E; Dąbrowska M; Gierlotka M; Kapica-Topczewska K; Karaszewski B; Kobayashi A; Krasiński Z; Kubica J; Kułakowska A; Kurek K; Ładny R; Pleban E; Rejdak K; Rydzewska G; Słowik A; Szopiński P; Woźniak A; Tycińska A
Kardiol Pol; 2024; 82(1):123-139. PubMed ID: 38230495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]